Abstract

This multicenter ACTG study is designed to evaluate the effect of megestrol acetate, with and without supplement of testosterone, in patients with HIV-associated wasting. Megestrol acetate is a potent appetite stimulant that has been shown to cause substantial weight gain in patients with wasting syndrome. However, the weight gain is predominantly, if not exclusively, fat. The observation that megestrol treatment results in a decrease in testosterone levels provides a possible explanation for the body composition changes that occur with this agent. Patients with HIV-associated wasting will be treated with megestrol acetate, 800 mg a day, and then randomized to receive either testosterone, 200 mg every other week, or testosterone placebo. After 12 weeks of double-blind treatment, all subjects will be eligible for combined therapy for an additional 12 weeks. Major outcomes include weight, body composition, quality of life, and monitoring for safety.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
3M01RR000083-37S1
Application #
6219466
Study Section
Project Start
1998-12-01
Project End
1999-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
37
Fiscal Year
1999
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Anderegg, Nanina; Johnson, Leigh F; Zaniewski, Elizabeth et al. (2017) All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up. AIDS 31 Suppl 1:S31-S40
Scherzer, Rebecca; Heymsfield, Steven B; Rimland, David et al. (2017) Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV monoinfection. AIDS 31:71-79
Abid, Z; Oh, S S; Hu, D et al. (2016) Maternal age and asthma in Latino populations. Clin Exp Allergy 46:1398-1406
Rahmani, Elior; Zaitlen, Noah; Baran, Yael et al. (2016) Sparse PCA corrects for cell type heterogeneity in epigenome-wide association studies. Nat Methods 13:443-5
Morrissey, Kari M; Stocker, Sophie L; Chen, Eugene C et al. (2016) The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers. Clin Pharmacokinet 55:495-506
Wright, Patrick W; Pyakurel, Ashmit; Vaida, Florin F et al. (2016) Putamen volume and its clinical and neurological correlates in primary HIV infection. AIDS 30:1789-94
Peters, Marion G; Bacchetti, Peter; Boylan, Ross et al. (2016) Enhanced liver fibrosis marker as a noninvasive predictor of mortality in HIV/hepatitis C virus-coinfected women from a multicenter study of women with or at risk for HIV. AIDS 30:723-9
Gonzales, C A; Bacchetti, P; Khalili, M (2016) Impact of gender and menopausal status on metabolic parameters in chronic hepatitis C infection. J Viral Hepat 23:232-9
Siewe, Basile; Pham, Joey T; Cohen, Mardge et al. (2015) Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma. AIDS 29:1659-64
Andreae, Michael H; Carter, George M; Shaparin, Naum et al. (2015) Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data. J Pain 16:1221-1232

Showing the most recent 10 out of 553 publications